Article PDF first page preview

First page of Adult Patients with Hbs-Only Phenotype of Sickle Cell Disease have a Decreased Arginine/Asymmetric Dimethylarginine Ratio

Objective: Leg ulcer is the most common cutaneous manifestation of sickle cell disease (SCD). Asymmetric dimethylarginine (ADMA) inhibits nitric oxide synthase, reducing nitric oxide availability and causing endothelial dysfunction. This study examined the relationship between arginine/ADMA ratio and leg ulcers in SCD. Methods: This was a cross sectional analytical study of 90 adult subjects including, 30 ‘HbS only’ with leg ulcer, 30 ‘HbS only’ without leg ulcer and 30 HbAA subjects. Plasma Arginine and ADMA levels were measured by ELISA method. Results: Median Arginine level, ADMA level, and Arginine/ADMA ratio were 21.05µmol/L, 3.0 µmol/L, and 7.41 respectively, for HbS-Only with leg ulcer; 25.9 µmol/L, 2.8 µmol/L, and 9.6 respectively, for HbS-Only without leg ulcer; and 47.8 µmol/L, 1.0 µmol/L (CI: 1.0-1.2), and 48.5 respectively for HbAA subjects. Median plasma L-arginine level was significantly lower in HbS with leg ulcer compared to HbS without leg ulcer (p < 0.001) and HbAA subjects (p < 0.001)). Conversely, median plasma ADMA level was significantly higher in HbS-Only with leg ulcer compared to HbS without leg ulcer (p = 0.002), and HbAA subjects (p < 0.001). Median Arginine/ADMA ratio was significantly lower in HbS-only patients with leg ulcer. Conclusions: The HbS-only patients with leg ulcers have lower Arginine, higher ADMA and lower Arginine/ADMA ratio when compared to those without leg ulcers and HbAA controls. The prospective Arginine/ADMA ratio should be studied to screen patients with higher risks of leg ulcers that could be prevented with specifically targeted care.

Journal Section:
Research Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial